Brief: Day One Biopharmaceuticals Expands Pipeline With Antibody Drug Conjugate Candidate For Adult And Pediatric Cancers

Day One Biopharmaceuticals

18/06/2024 14:23

June 18 (Reuters) - Day One Biopharmaceuticals Inc
 DAWN.O :
    * DAY ONE EXPANDS PIPELINE WITH POTENTIAL FIRST-IN-CLASS
CLINICAL-STAGE ANTIBODY DRUG CONJUGATE (ADC) TARGETING PTK7 IN
SOLID TUMORS FOR ADULT AND PEDIATRIC CANCERS
    * DAY ONE BIOPHARMACEUTICALS INC: MABCARE WILL RECEIVE $55
MILLION
UPFRONT
    * DAY ONE BIOPHARMACEUTICALS: MABCARE ELIGIBLE TO RECEIVE
ADDITIONAL $1.152 BILLION IN DEVELOPMENT, REGULATORY AND
COMMERCIAL SUCCESS-BASED MILESTONES
    * DAY ONE BIOPHARMACEUTICALS INC: EXPECTS FIRST PATIENT TO
BE
DOSED IN PHASE I STUDY IN Q4 OF 2024 OR Q1 OF 2025
    * DAY ONE BIOPHARMACEUTICALS: GOT INTO EXCLUSIVE LICENSING
AGREEMENT WITH MABCARE THERAPEUTICS FOR MTX-13

Source text for Eikon:  ID:nGNX7P3KnZ 
Further company coverage:  DAWN.O 

 ((Reuters.Briefs@thomsonreuters.com;))